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Abstract 
Prevention is the most promising way to reduce the high personal, familial, societal, clinical and 
economic costs of mental disorders in Europe and worldwide. A complementary approach is to 
go beyond the prevention of mental ill health, to promote good mental health. This manuscript 
highlights the first European consortium fostering cutting-edge multidisciplinary research in 
these two areas. The ECNP-funded Network on the Prevention of Mental Disorders and Mental 
Health Promotion (ECNP PMD-MHP) brings together European sites of excellence with different 
expertise for translational research collaboration, including partnerships with the industry. The 
ECNP PMD-MHP Network adopts a transdiagnostic, lifespan, clinical staging model which cuts 
across different mental disorders and different methodologies. The main aims of the ECNP PMD- 
MHP Network are to facilitate multidisciplinary collaboration, enhance knowledge and data 
sharing, standardise core assessment and outcome measures, promote clinical research, apply 
for grant funding, and generate research reports. By supporting collaborative research, the 
ECNP PMD-MHP NETWORK 1303 
ECNP PMD-MHP Network will be vital for fostering European psychiatry in the field of prevention 
of mental disorders and promotion of good mental health. 
© 2019 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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r. Introduction 
 major barrier to improving outcomes of mental disorders 
s that after the onset of the disorder has occurred, there
re limited treatment possibilities and even fewer options 
o alter the illness course ( Millan et al., 2016 ). Thus, preven-
ion is the most promising way to reduce the high personal,
amilial, societal, clinical and economic costs of mental dis- 
rders in Europe and worldwide ( Fusar-Poli et al., 2017a ).
he most validated preventive paradigm has focused on in- 
icated primary prevention ( Table 1 )( Arango et al., 2018 ) in
ndividuals presenting with subtle signs and symptoms, such 
s those at clinical high-risk for psychosis ( Fusar-Poli, 2017 ,
018 ; Fusar-Poli et al., 2013a ) or those at risk for bipolar
isorders ( Bechdolf et al., 2014 ; Correll et al., 2014 ; Fusar-
oli et al., 2018 ; Leopold et al., 2012 ; Pfennig et al., 2014a ,able 1 Classification of preventive approaches in psychiatry int
lassification of physical illness ( WHO, 2004 ). Gordon’s universal, 
ithin primary prevention in the public health classification [( WHO, 
lassic public health classification of prevention 
rimary prevention seeks to prevent the onset (incidence) 
f a disorder or illness [( WHO, 2004 ), page 17, Box 2] 
econdary prevention seeks to lower the rate of established 
ases of the disorder or illness in the population (prevalence) 
hrough early detection and treatment of diagnosable 
iseases [( WHO, 2004 ), page 17] 
ertiary prevention includes interventions that reduce 
isability, enhance rehabilitation and prevent relapses and 
ecurrences of the illness[( WHO, 2004 ), page 17] 
Mental disorder prevention aims at reducing incidence, prevalenc
symptoms, or the risk condition for a mental illness, preventing or d
in the affected person, their families and the society ( Institute of M014b ; Scott et al., 2017 ), depression( Loechner et al., 2018 ;
orrell et al., 2016 ; Rachid, 2018 ), or anxiety disorders
 Moreno-Peral et al., 2017 ). Complementary emerging ap-
roaches include selective primary prevention , targeting 
symptomatic individuals with specific risk factors for men- 
al disorders, and universal primary prevention , which can
e applied at scale in the general population ( Berk et al.,
017 ; Radua et al., 2018 ). Primary prevention interven-
ions seek to lower the incidence of mental disorders and
re embedded in a clinical staging ( Berk et al., 2017 ;
adua et al., 2018 ) and transdiagnostic ( Fusar-Poli et al.,
017b ) model and are applied across the life span, encom-
assing the prenatal period, post-natal development, child- 
ood, adolescence, early and late adulthood ( Berk et al.,
017 ; Morrell et al., 2016 ; Radua et al., 2018 ). Sec-
ndary prevention seeks to lower the prevalence of mentalegrates the classic public health classification with Gordon’s 
selective and indicated preventive interventions are included 
2004 ), page 17]. 
Gordon’s classification of prevention of physical illness 
( Gordon, 1983 ) 
Universal prevention is defined as those interventions that 
are targeted at the general public or to a whole population 
group that has not been identified on the basis of increased 
risk : targeted at the general public [( WHO, 2004 ), page 17, 
Box 3]. 
Selective prevention targets individuals or subgroups of the 
population whose risk of developing a mental disorder is 
significantly higher than average, as evidenced by biological, 
psychological or social risk factors [( WHO, 2004 ), page 17, 
Box 3]. 
Indicated prevention targets high-risk people who are 
identified as having minimal but detectable signs or 
symptoms foreshadowing mental disorder or biological 
markers indicating predisposition for mental disorder but 
who do not meet diagnostic criteria for disorder at that time 
[( WHO, 2004 ), page 17, Box 3]. 
e, recurrence of mental disorders, the time spent with 
elaying recurrences and also decreasing the impact of illness 
edicine, 1994 ) 
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 disorders while tertiary prevention seeks to reduce re-
lapses, disability and chronicity: these strategies can fur-
ther be employed in later adulthood to improve outcomes of
psychiatric disorders ( Berk et al., 2017 ; Radua et al., 2018 ).
Over the past decade, several European research sites have
produced accumulating evidence in this field, generating an
unexploited collaborative potential to foster breakthrough
disease-modifying preventive research ( Millan et al., 2016 ).
Barriers to multidisciplinary collaboration, knowledge and
data sharing, standardisation of core assessment and out-
come measures and collaborative grant funding applications
limit the current impact of European research in this field. 
A parallel line of evidence has clearly shown that ef-
fective interventions in this area should not only prevent
mental ill-health, but also promote good mental health
( Sharma et al., 2017 ). While there is an undoubtable
degree of overlap between prevention of mental disorders
and mental health promotion, the latter has remained on
the margins in Europe, mostly because of heterogeneous as-
sessment and outcome measures and the lack of robustly
validated interventional frameworks for clinical practice
( Saxena et al., 2006 ). 
This manuscript presents the first European research con-
sortium which has been established to tackle the above-
mentioned limitations of knowledge, and foster research for
the prevention of mental disorders and promotion of good
mental health. 
2. Experimental procedures 
This manuscript originates from a reflective workshop on
the progress, challenges and future directions of the pre-
vention of mental disorders and promotion of mental
health, which was held on the October 7, 2018, at the 31st
Congress of the European College of NeuroPsychopharma-
cology (ECNP) in Barcelona. Principal investigators from a
variety of European clinical academic centres that are ac-
tive in the field of prevention of mental disorders and pro-
motion of mental health were invited to join a new ECNP
Thematic Working Group on the Prevention of Mental Dis-
orders and Mental Health Promotion (ECNP PMD-MHP). Over
the subsequent year the group has received official approval
and funding as full ECNP Network. During the workshop, par-
ticipants also refined the Terms of Reference for the ECNP
PMD-MHP Network. The current manuscript summarises the
core results of this workshop, reviewing the ECNP Network
structure, aims of the ECNP PMD-MHP Network, participat-
ing centres with scientific track record, industry collabora-
tions and planned activities. The articles included in this
targeted review were not selected on a systematic basis,
and there is no assumption that the evidence discussed is
exhaustive. 
3. Results 
3.1. ECNP network taskforce 
ECNP Networks are scientific multi-disciplinary pan-
European platforms that bring together researchers with
different expertise for translational research collaborationsin the ECNP community (see Section 3.3 ). ECNP Networks
are established to facilitate the collection of essential data
in a harmonised way and can focus on specific brain dis-
orders or methodologies, flexibly supporting novel and tar-
geted collaborations across other existing ECNP Networks.
Usually, ECNP Networks and Thematic Working Groups are
instigated by specific research calls or promising initiatives.
The ECNP Networks are guided by the Networks Board, while
each Network is led by a chair and a co-chair. Chairs and co-
chairs of the Networks form the ECNP Network Taskforce. 
3.2. Aims of the ECNP PMD-MHP Network 
Overarching aims of the ECNP Network Taskforce include
fostering collaboration and gathering of experts on a spe-
cific topic, organising and promoting several Network meet-
ings, providing administrative support, facilitating dialogue
with stakeholders, supporting grant applications, and dis-
seminating the results of funded projects. 
The ECNP PMD-MHP Network was created in response to
several European funding initiatives in the field of preven-
tion of mental disorders or mental health promotion. For
examples, this initiative aligns with the European Commis-
sion’s ROAMER (A Roadmap for Mental Health Research in
Europe). The ECNP PMD-MHP Network adopts a transdiag-
nostic ( Fusar-Poli et al., 2019 ), lifespan approach to facil-
itate its broader integration with the other existing ECNP
Networks that focus on specific brain disorders. 
The ECNP PMD-MHP Network is highly multidisciplinary,
including basic researchers, psychiatrists, psychologists
and neuroscientists. Further multidisciplinary collabora-
tions have been established with industry companies (see
Section 3.4 ). The European sites included in the ECNP PMD-
MHP Network are centres of excellence in the prevention of
mental disorders and promotion of good mental health, and
are part of this TWG with the following shared goals: 
1. Facilitate multidisciplinary collaboration, knowledge
and data sharing building on existing ECNP Networks to
support innovative translational research, from basic to
clinical and public health research, for the benefit of pa-
tients, focusing on the transdiagnostic disease-modifying
prevention of mental disorders. 
2. Standardise core assessment, outcome measures and in-
terventional research strategies for the promotion of
mental health in Europe. 
3. Promote clinical research partnerships across disciplines
and sectors, including public–private partnerships, in
particular with the pharmaceutical firms, charities and
the public. 
4. Apply for European grant funding and produce research
reports to disseminate the findings of the PMD-TWG Net-
work via international journals. 
3.3. Core participating centres and scientific 
expertise 
The ECNP PMD-MHP Network is composed of core institu-
tions with an outstanding track record in the field of preven-
tion of mental disorders or mental health promotion. The
ECNP PMD-MHP Network is co-chaired by PFP and CA. 
ECNP PMD-MHP NETWORK 1305 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Department of Psychosis Studies, Institute of Psychia- 
try, Psychology and Neuroscience (IoPPN), King’s College 
London, London, UK. Members: PFP and PM. 
The Department of Psychosis Studies has conducted pio- 
neering work in the field of prevention of mental dis- 
orders resulting in over 1300 scientific publications, 
with a current £25 million in research grant income, 
with a specific focus on the development of new treat-
ments for early psychosis. It hosts one of the oldest and
largest clinical services for patients at risk of psychosis 
in Europe (Outreach and Support In South-London, OA- 
SIS Fusar-Poli et al., 2013b ). This service is providing
early detection, prognostic assessment and preventive 
treatment for individuals aged 14–25 who are at risk 
of developing psychosis, covering a catchment area of 
about 1.4 million Londoners ( Fusar-Poli et al., 2015 ).
This Department is currently investigating experimental 
psychopharmacological treatments for psychosis pre- 
vention, such as intranasal oxytocin, potassium channel 
modulators, phosphodiesterase inhibitors and cannabi- 
noid antagonists or modulators, in combination with 
precision and stratification medicine. This Department 
has long-standing expertise in managing research net- 
works (e.g. PSYSCAN, HARMONY, Table 2 ) and experi- 
mental therapeutics (STEP, CANTOP-RCT, Table 2 ). This 
Department (through PFP) coordinates the ECNP PMD- 
MHP Network, organising the meetings and the events. 
2. Brain and Behavioral Sciences Department, University of 
Pavia, Pavia, Italy. Member: PFP. 
The Department of Brain and Behavioral Sciences hosts 
the first Italian clinical service for the detection and 
treatments of underage children and adolescents at 
clinical risk of developing psychosis ( Spada et al., 2016 ).
This Department is studying the neurodevelopmental 
processes that precede the onset of major psychiatric 
disorders in children, the clinical and neuropsychologi- 
cal characteristics of help-seeking adolescents at risk of 
mental disorders, neuropsychological and brain imaging 
markers for the transition to psychosis and experimental 
therapeutics (e.g. FACT trial, Table 2 ). 
3. Hospital General Universitario Gregorio Marañón de 
Madrid, Centro de Investigación Biomedica en Red de 
Salud Mental, CIBERSAM. Member: CA. 
CIBERSAM’s main objective is carrying out excellence 
translational research helping to prevent mental disor- 
ders and thus provide a better quality of life for the gen-
eral population as well as better treatments for those 
with psychiatric disorders ( Salagre et al., 2019 ). The De-
partment of Child and Adolescent Psychiatry at Hospi- 
tal Gregorio Marañon has a long tradition in longitudinal 
studies with early first episode patients and children and 
adolescents at high risk to develop psychosis. 
4. Basel Department of Psychiatry (UPK), University of 
Basel, Basel, Switzerland. Member: SB. 
This Department runs one of the first clinical early 
recognition services in Europe, established in 1999. 
This Basel Early Treatment program covers a catch- 
ment area of 500.000 including adolescents and adults. 
This Department has longstanding expertise in study- 
ing the neurobiological correlates of emerging mental 
disorders, using modern neuroscientific methods such 
as structural, functional and multimodal neuroimaging. This Department also has a track record in early in-
tervention and exploring preventive and experimental 
therapeutics (nurtriens, LSD, microbiota), and experi- 
mental therapeutics (LSD, microbiota) and in managing 
international studies (e.g. PRONIA, EU-GEI, HARMONY, 
SYNSCHIZ). 
5. Department of Psychiatry and Psychotherapy, University 
of Lübeck. Member: SB 
This Department runs a newly established Translational 
Psychiatry Unit (TPU) focusing on the development of 
preventive methods and novel therapeutic tools to tar- 
get psychiatric disturbances as early as possible in life.
By having an early intervention clinical service for ado-
lescents and adults with non-affective and affective 
psychotic symptoms along with corresponding research 
groups utilizing a range of methods from neuroimaging, 
genetics, psychological, molecular and human experi- 
mental medicine, preventive strategies will be utilized 
into clinical practice. This Department covers a mainly 
rural catchment area of about 2 million people across 
the region of northern Germany. 
6. Department of Psychiatry and Psychotherapy, Ludwig- 
Maximilian-University, Munich, Germany. Member: NL. 
This Department hosts a clinical service for the detec-
tion of emerging mental disorders in children and ado-
lescents. From a research perspective, this Department 
leads the field of predictive analytics by using neuro-
biological and behavioural data to improve treatment 
of emerging mental disorders. The additional expertise 
of this Department includes precision psychiatry and in- 
dividualised stratification of risk for poor disease out- 
comes, and an improved understanding of the diagnos- 
tic boundaries between and within disease entities. This 
Department is leading or participating in international 
studies in this field (e.g. PRONIA, HARMONY). 
7. Department of Psychiatry, Warneford Hospital, Univer- 
sity of Oxford, Oxford. Member BL. 
This Department explores the neuro-immunological ba- 
sis of emerging mental disorder, in particular, the preva-
lence of antibodies against the NMDA receptor, and 
other neuronal targets, in people with early psychosis. 
This Department collaborates with academic groups and 
clinicians internationally to advance our understanding 
of emerging mental disorders and to treat patients with
the best evidence-based treatments. 
8. Department of Psychiatry, Amsterdam University Med- 
ical centers (location AMC), Amsterdam, Netherlands. 
Member: DN. 
This Department is particularly experienced in investi- 
gating transdiagnostic biomarkers that may indicate a 
risk of developing severe mental disorders in adoles- 
cents and young adults. One of the topics is the use of
neurophysiological methods for stratification medicine 
and refinement of risk prediction. Additionally, the De- 
partment conducts research in the use of eHealth ap-
proaches (ENYOY, Table 2 ) to help young people at risk
for severe mental illness. 
9. Central Institute of Mental Health in Mannheim, 
Mannheim, Germany. Member: AML. 
The Central Institute of Mental Health is the largest psy-
chiatric research institute in Germany. Its Department 
of Psychiatry and Psychotherapy has a longstanding 
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Table 2 Current portfolio of research programmes funded in the field of prevention of mental disorders or mental health promo- 
tion in the ECNP PMD-MHP Network. 
Research programme Funder Amount Period ECNP 
PMD-MHP 
Network site 
Topic 
PRONIA Personalised Prognostic Tools 
for Early Psychosis Management 
EU-FP7 Eur 6000000 2014–
2019 
Munich, 
Basel 
Development of a 
personalised tool to 
predict outcomes in 
patients at risk of 
psychosis 
PSYSCAN Translating neuroimaging 
findings from research into 
clinical practice 
EU-FP7 Eur 6000000 2014–
2020 
London Development of a 
personalised tool to 
predict outcomes in 
patients at risk of 
psychosis 
STEP Stratification & Treatment in 
Early Psychosis 
Wellcome 
Trust 
GBP 
15000000 
2020–
2025 
London Precision psychiatry and 
therapeutics for 
emerging psychosis 
SYNSCHIZ Linking synaptic dysfunction to 
disease mechanisms in 
schizophrenia - a multi-level 
investigation 
NEURON-ERA- 
NET 
EUR 
1733366 
2018–
2021 
Basel Translational approaches 
in disease development 
HARMONY Harmonization of At Risk 
Multisite Observational 
Networks for Youth 
NIMH US Dollars 
750000 
2015–
2020 
Munich, 
London, 
Basel 
Standardisation of 
prediction algorithms 
across existing research 
consortia in emerging 
psychosis 
CANTOP-RCT CANnabidiol as a Treatment fOr 
Psychosis clinical high-risk 
state- a Randomised Clinical 
Trial 
NIHR GBP 
1854492 
2019–
2024 
London Experimental 
therapeutics for the 
prevention of psychosis 
IMAGEMEND IMAging GEnetics for MENtal 
Disorders 
EU-FP7 Eur 6000000 2013–
2019 
Mannheim Development of 
transdiagnostic tools 
combining imaging 
genetics and clinical 
course to predict clinical 
course 
FACT Fluoxetine vs Aripiprazole 
Comparative Trial 
Local funding Eur 65000 2015–
2024 
Berlin, Pavia Experimental 
therapeutics for the 
prevention of psychosis 
and improvement of 
outcome 
ENYOY ENgage YOung people earlY ZonMw Eur 460656 2018–
2022 
Amsterdam Early engagement of 
young people with 
eHealth approaches to 
prevent severe mental 
illness 
EPI_young Epigenome dysregulation in 
link with substance use and 
mental health in young people 
Ministry of 
Research 
grant 
Eur 350000 2017–
2021 
Paris Epigenetic modulation of 
mental health problems 
in young people 
FOOD4THOUGHT 
Dietary patterns in prevention 
and treatment of mental 
disorders 
ZonMw Eur 50000 2017–
2019 
Maastricht Impact of food/diet in 
the 
prevention/treatment of 
mental disorders 
@ease Youth mental health reform by 
improving access to care 
Innovation 
Fund/ 
Municipalities 
Eur 500000 2017–
2020 
Maastricht, 
Amsterdam 
Implementation of 
anonymous intervention 
for youth 12–25 with 
mental health needs 
( continued on next page ) 
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Table 2 ( continued ) 
Research programme Funder Amount Period ECNP 
PMD-MHP 
Network site 
Topic 
SELFIE Early transdiagnostic 
self-management intervention 
in youth 
ZonMw Eur 400000 2018–
2022 
Maastricht Ecological momentary 
intervention in youth 
12–25 
STAR-T Stress in at-risk mental state: 
efficacy of stress management 
cognitive behavioural 
therapy:a randomized 
controlled trial 
Ministry of 
health 
Eur 568000 2014–
2019 
Paris Experimental trial for 
the prevention pf 
psychosis and epigenetic 
changes related to 
psychosis conversion 
EDIPAJ Efficiency of early intervention 
services on access to care in 
young patients with early 
psychosis 
Ministry of 
health 
Eur 673600 2019–
2022 
Paris Implementation of EIS 
and Cost efficiency study 
SCOPe Self-administered COgnitive 
Personalized training in early 
psychosis: a randomized 
controlled trial in adolescents 
and young adults 
Ministry of 
health 
Eur 720600 2019–
2023 
Paris Implementation of 
e-Health approaches for 
emerging mental 
disorders 
REDRESS Early Prediction of 
non-response to Antidepressant 
therapy via a mobile digital 
scale 
Ad Scientiam Eur 600000 2018–
2020 
Paris Implementation of 
e-Health approaches for 
emerging mental 
disorders 
 
1
1
 
1
 
 
 
 
1
 
 
 
 scientific reputation for the study of environmental and 
genetic indicators of emerging mental illness using a 
combination of neuroscientific methods with ecological 
momentary assessment, and the neural mechanisms of 
complex social behaviour in children and adolescents 
(IMAGEMEND). It coordinates the ESPRIT consortium, 
which aims at prevention in a clinical high-risk popula- 
tion and has worked on mechanisms underlying common 
societal risk context such as urban living. The long-term 
goal of this research programme is to move these mech-
anistic insights into the development of novel treat- 
ments for the prevention of mental disorders. 
0. Center for Psychiatric Neuroscience, Department of Psy- 
chiatry, University Hospital Center and University of 
Lausanne, Prilly-Lausanne, Switzerland. Member: KQD. 
The Center for Psychiatric Neuroscience aims at bridg- 
ing basic neuroscience and emerging mental disorders. 
The work conducted at this centre showed that oxida- 
tive stress/redox dysregulation may represent a "hub" 
on which both genetic and environmental risk factors 
converge during neurodevelopment, leading to the im- 
pairment of neural connectivity and synchronization, 
and the emergence of mental disorders. Current re- 
search studies conducted in this environment are inves- 
tigating biomarkers for early detection and developing 
innovative therapeutics to impact the development of 
emerging mental disorders. 
1. INSERM, Laboratoire de Physiopathologie des Maladies 
Psychiatriques, Centre de Psychiatrie et Neurosciences, 
Université Paris Descartes, Paris, France. Member: MOK. 
INSERM’s expertise focuses on the identification of de- 
velopmental forms of emerging mental disorders and on 
exploring the interaction between substance abuse and 
emerging mental disorders (EPI_young, Table 2 ). Cur- rent lines of research involve the assessment of new en-
dophenotypic markers for stratifying individuals at risk 
for psychosis and epigenetic changes associated to psy- 
chosis onset (REDRESS, STAR-T, EDIPAJ, SCOPe Table 2 ). 
2. Department of Psychiatry and Psychology, Maastricht 
University, Maastricht, The Netherlands. Member: TVA. 
The Department of Psychiatry and Psychology employs 
neuroscientific methods to investigate the fragile tran- 
sitional phases from childhood to adulthood. Besides, 
this centre adopts a transdiagnostic approach to inves- 
tigate novel treatments and biomarkers across different 
types of emerging mental disorders (FOOD4THOUGHT, 
SELFIE). In addition, the department is leading or par-
ticipating in large international studies in populations 
at high risk for psychosis (PSYSCAN, HARMONY). More- 
over, the department is leading in national youth mental
health reform and opened the first @ease center ( www.
ease.nl ), the Dutch version of the Australian Headspace.
3. Department of Child and Adolescent Psychiatry, Psycho- 
somatics and Psychotherapy, Charité Universitätsmedi- 
zin, Berlin, Germany. Member: CC 
The Department of Child and Adolescent Psychia- 
try, Psychosomatics and Psychotherapy, Charité Univer- 
sitätsmedizin, Berlin, Germany has one specific focus on 
the early identification, prevention and intervention of 
youth and young adults at-risk for the development of
psychosis and affective disorders. As part of a collabora-
tive service between the child and adolescent and adult
psychiatry departments at the Charité Berlin, early de- 
tection, prognostic assessment and preventive treat- 
ment for individuals aged 12–25 is provided who are at
risk of developing non-affective or affective psychosis 
is provided. Spanning a network of different Univer- 
sity and non-University child and adolescent and adult 
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 psychiatry departments, covering a combined catch-
ment area of about 2.0 million people, the department
is engaged in high-risk and prevention research across
the region of greater Berlin region (e.g., FACT, Table 2 ).
4. Department of Psychiatry, Psychotherapy and Psycho-
somatic Medicine with Early Intervention and Recog-
nition Centre (FRITZ), Vivantes Klinikum Am Urban
and Vivantes Klinikum im Friedrichshain, Charité-
Universitätsmedizin, Berlin, Germany: Member: AB. 
The Department of Psychiatry, Psychotherapy and Psy-
chosomatic Medicine has a longstanding expertise in
studying psychosocial interventions in emerging men-
tal disorders and in exploring psychopathological and
psychosocial predictors of illness onset. Together with
the Department of Child and Adolescent Psychiatry,
Psychosomatics and Psychotherapy at Charité Univer-
sitätsmedizin, the department is spanning a network of
child and adolescent and adult psychiatry departments
focussing on high-risk and prevention research across
the region of Berlin. Besides this, the centre adopts a
transdiagnostic approach to investigate the course of
emerging mental disorders. 
5. Department of Psychiatry, University of Campania Luigi
Vanvitelli, Naples, Italy. Member: SG 
The Department has two inpatient wards, several out-
patient facilities, a rehabilitation centre, a biochemical
lab, a genetic lab, an electrophysiology lab and a neu-
ropsychology lab. A unit of the outpatient facilities is
dedicated to screening, recruitment and assessment of
patients at risk of psychosis or with first episode psy-
chosis. Facilities are available for early intervention, in-
cluding psychotherapy, cognitive training and psychoso-
cial treatments. The unit has gained a wide experience
in research in the field, due to the participation in in-
ternational investigations involving these patient pop-
ulations (PSYSCAN). Moreover, it has well established
clinical and research collaborations with a network of
13 Mental Health Departments located in the city of
Naples and the Campania region, each of them with a
catchment area ranging from 164,000 to 1000,000 in-
habitants. Moreover, several departments in the area
refer young undiagnosed subjects to our Department to
assess risk for mental disorders. The Department also
coordinates the activities of the Italian Network for Re-
search on Psychoses, including 26 University Centers. 
Furthermore, the ECNP PMD-MHD Network includes
members and centres and therefore expertise and
infrastructures- that are already participating in other es-
tablished ECNP Networks as follows: 
• Schizophrenia Network (SG, PFP, CA); 
• Bipolar Disorder Network (MB, LVK, CC, AB, AP); 
• Anxiety Disorders Research Network ADRN (KD); 
• Preclinical Data Forum Network (MM); 
• Obsessive Compulsive and Related Disorders Network
OCRN (CA); 
• Child and Adolescent Neuropsychopharmacology Net-
work (CA, CC); 
• Experimental Medicine Network (CA); 
• Neuroimaging Network (NK, AML);  3.4. Collaboration with the pharmaceutical 
industry 
A key remit of the ECNP PMD-MHP Network is to foster col-
laborative translational research with the industry in the
field of prevention of mental disorders. Researchers from
Lundbeck LTD (AW), Boehringer-Ingelheim (MS) and Servier
(MJM) are part of the ECNP PMD-MHP Network. The geo-
graphical composition of the core ECNP PMD-MHP Network
is detailed in Fig. 1 (with the exclusion of the Boehringer-
Ingelheim member from the US). 
4. Discussion 
The ECNP PMD-MHP Network is the first European infras-
tructure which is specifically aiming at improving the pre-
vention of mental disorders and mental health promotion.
Such an ambitious goal will be achieved through an inte-
grated approach. First, the ECNP PMD-MHP Network will
facilitate the much-needed cross-fertilisation of transdisci-
plinary expertise across leading European institutions that
is necessary to overcome current obstacles in this area.
Ideally, cross-fertilisation would ultimately be expanded
to efforts to improve mental health in the elderly and to
prevent neurodegenerative disorders of ageing, such as de-
mentia, which are characterized by disabling yet often ne-
glected psychiatric symptoms like psychosis. The ECNP PMD-
MHP Network’s outstanding portfolio of European and in-
ternational collaborations on the prediction of outcomes in
young people with emerging mental disorders, promotion
of good mental health or experimental preventive inter-
ventions demonstrates its capacity to cut across different
sectors and disciplines of medical, neuroscientific and psy-
chological knowledge. Such an approach aligns with other
European initiatives such as the European Alliance Against
Depression ( http://eaad.net ) which was established in 2008
by a number of mental health experts from different Euro-
pean research to improve care and optimise treatment for
patients with depressive disorders and to prevent suicidal
behaviour. Second, the ECNP PMD-MHP Network will enable
data sharing opportunities and harmonisation of measure-
ments, which are essential to advance knowledge at times
of big-data research. This will be facilitated through spe-
cific scientific initiatives encompassing evidence synthesis
approaches, use of data-sharing cloud system, development
of specific grant applications, organisation of collaborative
satellite symposia and events. Third, the combination of big
data and multidisciplinary collaboration will, in turn, trans-
late into large-scale grant applications to European funding
bodies. The resulting research activities are likely to im-
prove the quality, competitiveness and efficiency of Euro-
pean research in the field of prevention of mental disorders
and promotion of mental health. Fourth, the ECNP PMD-MHP
Network will play a pivotal role in disseminating the pro-
duced outputs through open-access scientific articles, work-
shops, seminars and symposia organised at European con-
ferences. Particular attention will be placed on supporting
young clinicians and researchers with interest in the pre-
vention of mental disorders and mental health promotion.
Fifth, the ECNP PMD-MHP Network will liaise with national
stakeholders and national policymakers to support the local
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Fig. 1 ECNP network for the prevention of mental disorders and mental health promotion ( https://www.ecnp.eu/ 
research- innovation/ECNP- networks/List- ECNP- Networks/Prevention- mental- disorders- and- mental- health- promotion- TWG . 
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emplementation of evidence-based, preventive policies and 
fforts to promote good mental health. 
Overall, these efforts are expected to blend into a new 
esearch culture that is sensitive to the prevention of men-
al disorders and mental health promotion, for the ultimate 
enefits of European citizens that may experience some 
railty in their mental health. 
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